Drug Guide
 

Trastuzumab-Emtansine

Bookmark
  •  
    IV infusion
    Trastuzumab-Emtansine
    Kadcyla 
    • Mechanism of Action
    • Contains a monoclonal antibody directed toward HER2 (trastuzumab), linked to a chemotherapeutic agent (DM1), allowing for targeted delivery of cytotoxic chemotherapy to HER2-positive tumour cells.
      Trastuzumab inhibits HER2 signalling pathways resulting in cell cycle arrest, and also mediates antibody-dependent cell-mediated cytotoxicity.
      DM1 is a cytotoxic agent that binds to tubulin, preventing polymerisation and resulting in cell cycle arrest in the G2/M phase.

Clinical Use

    • Indication
    • HER2-positive metastatic breast cancer refractory to trastuzumab.
    • Adverse Effects
    • Bone marrow suppression – leucopaenia, anaemia, thrombocytopaenia
    • Immunosuppression (susceptibility to infection)
    • Nausea / vomiting / diarrhoea
    • Abdominal pain
    • Cardiac dysfunction
    • Dyspnoea / wheeze
    • Peripheral neuropathy
    • Arthralgias / myalgias
    • LFT derangement
    • Headache
    • Dizziness
    • Flushing
    • Weight loss
    • Insomnia
    • Rash
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge
Explore
   
 
Feedback